Younger Age and Lower C-Reactive Protein Levels Predict Successful Tapering of Biologics in Patients...
New research presented at the 2017 annual meeting of the American College of Rheumatology (ACR) and the Association of Rheumatology Health Professionals (ARHP) shows that certain factors make some patients with rheumatoid arthritis (RA) more likely to have success tapering biologic disease-modifying antirheumatic drugs (DMARDs).
Secukinumab Eases Anxiety and Depression in Patients with Psoriatic Arthritis and Moderate to Severe...
Patients with psoriatic arthritis (PsA) or psoriasis are at greater risk for psychological distress, including depression and suicidality.
Secukinumab, a fully human monoclonal antibody that selectively neutralizes interleukin-17A, has demonstrated efficacy, short-term safety, rapid onset of action, and sustained responses in patients with moderate to severe plaque psoriasis or psoriatic arthritis (PsA).
Patients with rheumatoid arthritis (RA) experience chronic pain, inflammation and stiffness in their joints, as well as possible inflammation in their organs.
Biological therapies for moderate to severe rheumatoid arthritis have significantly improved treatment and prognosis. However, the high cost of treatment may be a barrier to access.